Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) was the recipient of a significant decline in short interest in the month of July. As of July 15th, there was short interest totalling 12,730,000 shares, a decline of 17.9% from the June 30th total of 15,510,000 shares. Based on an average daily volume of 6,250,000 shares, the days-to-cover ratio is presently 2.0 days.
Sangamo Therapeutics Trading Up 28.7 %
Shares of NASDAQ:SGMO traded up $0.19 on Friday, reaching $0.86. 123,708,543 shares of the company’s stock were exchanged, compared to its average volume of 18,010,276. The company has a fifty day moving average of $0.49 and a 200-day moving average of $0.61. Sangamo Therapeutics has a twelve month low of $0.29 and a twelve month high of $1.48. The company has a market capitalization of $179.48 million, a price-to-earnings ratio of -0.46 and a beta of 1.24.
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.05). Sangamo Therapeutics had a negative return on equity of 182.55% and a negative net margin of 1,749.06%. The company had revenue of $0.48 million for the quarter, compared to analyst estimates of $8.51 million. During the same period last year, the company posted $0.12 earnings per share. As a group, equities research analysts forecast that Sangamo Therapeutics will post -0.55 EPS for the current fiscal year.
Institutional Trading of Sangamo Therapeutics
Wall Street Analysts Forecast Growth
Several equities analysts have commented on SGMO shares. StockNews.com started coverage on shares of Sangamo Therapeutics in a report on Sunday. They issued a “sell” rating on the stock. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Sangamo Therapeutics in a research report on Wednesday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $5.67.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Read More
- Five stocks we like better than Sangamo Therapeutics
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Top Stocks Investing in 5G Technology
- Why Call Options Volume for These 2 Stocks Spiked Together
- 3 Fintech Stocks With Good 2021 Prospects
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.